366 Studies Now Enrolling
Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
COPERNICUS: A study to treat non-small cell lung cancer (NSCLC)
| Sponsor: | Janssen |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAV5314 |
| U.S. Govt. ID: | NCT06667076 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to understand more about the combination of amivantamab and lazertinib in non-small cell lung cancer (NSCLC) who have a specific mutation in the EGFR (epidermal growth factor receptor) gene and have not had prior treatment for their disease. The Food and Drug Administration (FDA) has not approved the combination of amivantamab subcutaneous (given as an injection under the skin) and lazertinib.
